Growing investment in rehabilitation robotics
The funding, which closed in late March 2026, comprises €6 million in equity from a consortium of family offices, entrepreneurs, and private investors, supplemented by €2 million in non-dilutive financing awarded through the France 2030 national investment programme. The blended structure reflects a pattern increasingly common among European medtech startups, where government innovation grants complement private capital to derisk the commercialisation of novel therapeutic devices.
Lifebloom’s core product, the Lifebloom One, is a robotic exoskeleton system designed to restore autonomous walking in patients with reduced mobility — conditions stemming from neurological injuries, strokes, spinal cord damage, and age-related mobility decline. Unlike fitness-oriented wearable robotics, the Lifebloom One is a clinical rehabilitation tool, deployed within healthcare facilities under medical supervision as part of structured therapy programmes.
Scaling deployment across French healthcare facilities
The primary use of funds is the rapid deployment of Lifebloom’s Walking Units, with the company targeting 30 healthcare facilities across France within the coming year. This rollout strategy is critical: exoskeleton rehabilitation technology has shown clinical promise for over a decade, but adoption has been constrained by high unit costs, limited insurance reimbursement pathways, and the need for specialised clinical training. Lifebloom’s approach — providing integrated walking units rather than standalone exoskeletons — is designed to lower the operational barrier for rehabilitation centres, packaging the hardware, software, and clinical support into a deployable system.
The company’s longer-term target is ambitious: enabling 1,000 patients to regain autonomous walking by 2028. While the number may appear modest in absolute terms, it represents a significant milestone in a field where each successful rehabilitation outcome requires dozens of supervised therapy sessions and careful patient selection.
European medtech finds its stride in rehabilitation robotics
Lifebloom’s funding arrives during a period of growing investor interest in rehabilitation and assistive robotics across Europe. The global rehabilitation robotics market, valued at approximately $1.2 billion in 2025, is projected to grow at a compound annual rate exceeding 20 per cent through the end of the decade, driven by ageing populations, rising stroke incidence, and mounting pressure on healthcare systems to deliver cost-effective long-term care.
In France specifically, the government’s France 2030 programme has emerged as a significant catalyst for medtech innovation, providing non-dilutive capital to companies developing breakthrough health technologies. The programme’s backing of Lifebloom signals institutional confidence in exoskeleton therapy as a viable component of France’s future rehabilitation infrastructure — a vote of confidence that may help accelerate regulatory and reimbursement pathways for the category.
Founded in 2019 and headquartered in Lille, Lifebloom has spent the intervening years refining its technology and building clinical evidence. The transition from development to deployment — marked by this funding round — represents the classic inflection point for European medtech companies: the moment when a promising laboratory technology must prove it can scale within the practical constraints of real-world healthcare delivery.
For the consortium of family offices and private investors backing the round, the thesis rests on a straightforward demographic reality: Europe’s population is ageing, its healthcare workforce is shrinking, and technologies that can multiply the effectiveness of rehabilitation professionals will command growing value. Lifebloom’s challenge now is execution — placing its Walking Units in clinics, training therapists, and generating the patient outcome data that will underpin broader adoption.
Summary
- Company: Lifebloom
- HQ: Lille, France
- Founded: 2019
- Round: Seed (equity + France 2030 grant)
- Amount: €8 million (€6M equity + €2M non-dilutive)
- Investors: Consortium of family offices, entrepreneurs, and private investors; France 2030 programme
- Use of funds: Deployment of Walking Units across 30 French healthcare facilities; target of 1,000 patients walking autonomously by 2028